CRANBURY, N.J.--(BUSINESS WIRE)--April 6, 2006--Valera Pharmaceuticals, Inc. announced today the successful completion of the active clinical portion of its Phase III study of Supprelin® LA, a 12-month implant for treating central precocious puberty (CPP), or the early onset of puberty. This multi-center, open-label study involved 36 patients, primarily female, who ranged in age from four to eleven years.
